Imanishi Naoko
   Department   University Hospital  General Thoracic Surgery, Clinical Departments
   Position  
Language English
Title IS2-6 The 25 cases of heart and great vessel resection innonsmallcelllungcancerpatients
Conference 第33回日本呼吸器外科学会総会
Conference Type Nationwide Conferences
Presentation Type Speech
Lecture Type General
Publisher and common publisherKojiKuroda,SyuichiShinohara,RintaroOyama,KenichiKobayashi,SakikoYura, HirokiMatsumiya,TaijiKuwata,MasaruTakenaka,YasuhiroChikaishi,SoichiOka, AyakoHirai,KazueYoneda,YukoTashima,YoshikaNagata,NaokoImanishi, FumihiroTanaka
Date 2016/05/13
Venue
(city and name of the country)
京都市/国立京都国際会館
Society abstract 日本呼吸器外科学会学術総会 30(3),36 2016
Summary Abstract Weanalyzedtheresultsofsurgicaltreatmentthathavebeenresectedtheheartandgreatvesselsfornonsmall cell lung cancer in our department from August 2011 to September 2015.The operators have determinedheartandgreatvesselsresectionwasnecessaryforcompleteresection.Greatvesselswerethesitesof that have been recognized as T4 great vessels in the lung cancer handling Terms seventh edition. Surgery related death and hospitality death were none. Heart and great vessels resection sites were left atrium 9/superiorvenacava8/pulmonaryvein(intrapericardium)7/rightbrachiocephalicvein1cases.ThecaseswereSex ratio male 18/Female 7, 4481 years of age(mean 62.9 years), right and left ratio 19/6,pathological type Sq 14/Ad 9/LCNEC 1/Ad+Sq 1, the tumor diameter 16110mm(average 48mm), preoperative treatment 9 (CRT8)/none16cases. Clinical stage was T1a/1b/2a/2b/3/4=1/2/8/4/0/8, N0/1/2/3=6/6/13/0, M0/1a/1b= 0/0/1cases.SurgicalprocedureswereRUL7(sleeve1)/RML1/RLL3(sleeve1)/RMLL4/RUML 3/RPN 1 andLUL5(sleeve3)/LPN1cases.ThePathologicalstagewasT1a/1b/2a/2b/3/4=2/2/10(y2a2)/1/0/7,N 0/1/2/3=9(y03)/7(y11)/9(y25)/0,M0/1a/1b=0/0/1.PreoperativetherapeuticeffectwasEf1a/1b/2/3 =0/4/4/1.SurvivalwascalculatedbytheKaplanMeiermethod.Observationperiodis771561days(average observationperiod607days).9caseswithoutrecurrence(36%),16caseswerewithrecurrence(64%).Resectionsitesthatshowednorecurrenceweresuperiorvenacava3andleftatrium2,pulmonaryvein4cases.Relapsefree survival was median 330 days, 1year recurrencefree survival 44%, 2year recurrencefree survival30%.Foroverallsurvival,1yearsurvivalratewas87%,2yearsurvivalrate61%.